
ARIA Associated with Aducanumab
Dr. Jeff Burns talks with Dr. Lon Schneider about the development of ARIA in the Phase 3 EMERGE and ENGAGE trials that led to the FDA's accelerated approval of aducanumab for the treatment of Alzheimer disease.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.